Recently unlocked door: a fresh permission, approval, or qualification is already producing first real business
The model's full reasoning — Q2 2022 call → NOWe need answer YES/NO based on transcript. Question asks if management describes company recently obtained permission/approval/qualification/certification/listing/access right it did not previously hold, and real first business through that newly opened door has already begun, with most ahead. Search transcript for such. Mentions CMS mandated review, not approval. SelectRx? They entered space last May, invested, enrolled 40k, active paying members 10k. Did they obtain permission/approval? No mention of regulatory approval or license or certification. It's a business expansion, not access right granted by outside authority. No. Answer NO.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| DXCM | DexCom, Inc. | Q4 2023 | 2024-02-08 | B+ |
| RDCM | RADCOM Ltd. | Q4 2023 | 2024-01-31 | A |
| PFE | Pfizer Inc. | Q4 2023 | 2024-01-30 | F |
| NVAX | Novavax, Inc. | Q3 2023 | 2023-11-09 | F |
| RVLV | Revolve Group, Inc. | Q3 2023 | 2023-11-01 | C |
| APPS | Digital Turbine, Inc. | Q1 2024 | 2023-08-08 | D |
| SIBN | SI-BONE, Inc. | Q3 2022 | 2022-11-07 | C+ |
| HBB | Hamilton Beach Brands Holding Company | Q3 2022 | 2022-11-05 | C |
| CMLS | Cumulus Media Inc. | Q3 2022 | 2022-10-28 | D |
| YMM | Full Truck Alliance Co. Ltd. | Q2 2022 | 2022-08-25 | C+ |
| CDXC | ChromaDex Corporation | Q4 2021 | 2022-03-09 | C+ |
| VNDA | Vanda Pharmaceuticals Inc. | Q4 2021 | 2022-02-23 | F |
| AGIO | Agios Pharmaceuticals, Inc. | Q3 2018 | 2018-11-01 | C |
| AMGN | Amgen Inc. | Q3 2018 | 2018-10-30 | B+ |
| MAS | Masco Corporation | Q3 2018 | 2018-10-30 | C |
| PRIM | Primoris Services Corporation | Q2 2018 | 2018-08-11 | C+ |
| ATI | Allegheny Technologies Incorporated | Q1 2018 | 2018-04-24 | B |
| HOLX | Hologic, Inc. | Q4 2017 | 2017-11-08 | D |
| BIIB | Biogen Inc. | Q2 2017 | 2017-07-25 | B |
| CNS | Cohen & Steers, Inc. | Q2 2017 | 2017-07-20 | B |
| IONS | Ionis Pharmaceuticals, Inc. | Q1 2017 | 2017-05-09 | C |
| PDCO | Patterson Companies, Inc. | Q3 2017 | 2017-02-23 | C |
| BMY | Bristol-Myers Squibb Company | Q4 2016 | 2017-01-26 | F |
| MAT | Mattel, Inc. | Q3 2016 | 2016-10-19 | C |
NVAX · Q3 2023 → YESThe question is: Does management describe that the company RECENTLY OBTAINED A PERMISSION, APPROVAL, QUALIFICATION, CERTIFICATION, LISTING, OR ACCESS RIGHT it did not previously hold — something grant...NO The transcript describes shipments of the updated COVID vaccine that began three weeks ago in the US after competitor launches, along with EU approval in October. However, these details do not meet the criteria for a YES answer because the transcript does not explicitly frame this as a newly obtained permission or access right that the company did not previously hold. Instead, it presents the launch as an update to their existing COVID-19 vaccine platform, with references to prior versions and the ability to update for seasonal strains.
MAT · Q3 2016 → YESThe question is about whether management describes that the company recently obtained a permission, approval, etc., that it didn't previously hold, and that real first business through that newly open...YES The transcript shows management describing a recent new partnership with Toys "R" Us for American Girl, granting exclusive store-within-store access that previously excluded the company. Initial shipping began in the first full quarter, with the distribution build still in early stages and most of the market potential ahead.
MAS · Q3 2018 → YESThe question is about whether management describes that the company recently obtained a permission, approval, etc., that it didn't previously hold, and that real first business through that newly open...YES The transcript shows management describing a recent program access at Menards that enables sales of stock cabinetry, with initial performance already underway and ramping toward an $80 million annual run rate in Q4—indicating the door is newly open and most of the potential volume remains ahead.